tirzepatide for obesity fda approval Grants a New Indication Management Obesity is increasingly addressed with

Quick Absorption: The non-greasy, fast-absorbing texture ensures easy application, allowing you to continue with your daily activities without any discomfort

Top-Line Summary: REDEFINE 4 (CagriSema vs Tirzepatide) - - - CagriSema: 23.0% weight loss (efficacy estimand) Tirzepatide: 25.5% weight loss Treatment-regimen estimand: CagriSema 20.2% Tirzepatide 23.6% Primary endpoint: Not met (non-inferiority) Safety: Mostly GI AEs, consistent with class Perspective: A therapy producing ~23% weight loss is framed as missing. Thats how far obesity pharmacotherapy has progressed

Recently, Ozempic has been prescribed by physicians off-label to help obese people lose weight easily

Rated 4 out of 5 Shelley W

Your history is the best predictor of your future response